Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

Tina Cascone, MD, PhD, of MD Anderson Cancer Center
Novel Perioperative Combinations Show Efficacy in Resectable NSCLC

September 8th 2024

Several novel combinations yielded high pCR and mPR rates in patients with resectable non–small cell lung cancer, according to data from the 2024 IASLC conference.

Caicun Zhou, MD, PhD, of Shanghai Pulmonary Hospital
Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in PD-L1+ Advanced NSCLC

September 8th 2024

Matthew Smeltzer, PhD, of The University of Memphis
Global Survey Examines Barriers to Optimal Lung Cancer Biomarker Testing

September 8th 2024

The OncFive: Top Oncology Articles for the Week of 9/1
The OncFive: Top Oncology Articles for the Week of 9/1

September 7th 2024

OncLive’s August Roundup of Key FDA Approvals in Oncology
OncLive’s August Roundup of Key FDA Approvals in Oncology

September 4th 2024

<1
...
105106107108109